SynthesisHeart failure reviews2025
Heart failure with preserved ejection fraction and atrial fibrillation: catheter ablation vs. standard medical therapy - a systematic review and meta-analysis.
Synthesis in Heart failure reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Meta-analysis of comprehensive prognostic evaluation in patients with atrial fibrillation complicated by heart failure after catheter ablation.Scientific reports · 2025Pooled it
- Comorbidities and incidence of heart failure with preserved ejection fraction: a systematic review and meta-analysis of cohort studies.BMJ open · 2025Pooled it
- Risk of Stroke, Thromboembolism and Mortality in Atrial Fibrillation Patients Across Different Stages and Types of Heart Failure: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Which Patient Benefits from Guideline-directed Medical Therapy for Heart Failure and Rate Control versus Rhythm Control in Patients with Congestive Heart Failure and Atrial Fibrillation and What are Those Therapies?Arrhythmia & electrophysiology review · 2026Review
- Updated Meta-Analysis of Catheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Preserved Ejection Fraction.Journal of arrhythmia · 2025Article
- Concomitant Atrial Fibrillation Ablation in Surgical Aortic Valve Replacement: A Systematic Review and Meta-Analysis.CJC open · 2025Review
- Safety and efficacy of catheter ablation in atrial fibrillation patients with heart failure with preserved ejection fraction.BMC cardiovascular disorders · 2025Article
- Risk of Acute Pain in Obese Patients Undergoing Atrial Fibrillation Ablation.Journal of pain research · 2025Article
- Atrial Fibrillation Ablation in Heart Failure and Preserved Ejection Fraction: An Observational Study of Risk Factors for Heart Failure Hospitalization.Current cardiology reviews · 2025Observational
- Catheter Ablation in Atrial Fibrillation: Recent Advances.Journal of clinical medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe latest guidelines advocate for catheter ablation (CA) over standard medical therapy (SMT) for managing atrial fibrillation (AF) in patients with heart failure with reduced ejection fraction (HFrEF). However, significant knowledge gaps exist regarding the effectiveness of CA vs. SMT in patients with heart failure with preserved ejection fraction (HFpEF).
methodsPubMed, Scopus, and Embase until February 2024 were systematically searched. Given the limited number of randomized studies, propensity score-matched observational studies comparing CA with SMT in AF patients with HFpEF were also included. The primary outcome was a composite endpoint of all-cause mortality and HF hospitalization.
resultsEight studies that enrolled 17,717 SMT and 2537 CA patients were included. CA was associated with a significantly lower risk of the composite endpoint of all-cause mortality and HF hospitalization (HR 0.61; 95% CI, 0.43-0.85). The risk of HF hospitalization (HR 0.44; 95% CI, 0.23-0.83), cardiovascular mortality (HR 0.43; 95% CI, 0.22-0.84), and AF recurrence (HR 0.53; 95% CI, 0.39-0.73) were also lower in the CA group.
conclusionCA demonstrated significant cardiovascular morbidity and mortality benefits compared to SMT in the HFpEF population.
Indexed as
Identifiers
39278992What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.